Novo Nordisk diabetes drugs showcased at EASD meeting

Presentations at the European Association for the Study of Diabetes (EASD) taking place in Stockholm, Sweden, today included several for products from Danish diabetes care giant Novo Nordisk (NOV: N).

New data from a post-hoc analysis of the Phase IIIa SCALE clinical development program were presented, demonstrating that adults in the SCALE Obesity and Prediabetes and SCALE Diabetes trials who lost at least 5% of their body weight after completing 16 weeks of Saxenda (liraglutide 3mg) treatment (defined as 'early responders') had greater weight loss after completing 56 weeks, compared with people losing less than 5% body weight with Saxenda after completing 16 weeks ('early non-responders'). All treatment groups included a reduced-calorie diet and increased physical activity.

"These data demonstrate the importance of identifying those adults who respond early to Saxenda," said Matthias Blüher, head of the obesity outpatient clinic at the University of Leipzig, Germany, and SCALE' trial investigator. "Not only are these Saxendaearly responders more likely to achieve greater weight loss over time, they are also more likely to experience greater improvements in cardiometabolic risk factors," he added.